



(43) International Publication Date
15 December 2016 (15.12.2016)

WIPO | PCT

(10) International Publication Number
WO 2016/201162 A1

- (51) International Patent Classification:
C12N 5/0775 (2010.01) C12N 15/86 (2006.01)
- (21) International Application Number:
PCT/US2016/036786
- (22) International Filing Date:
10 June 2016 (10.06.2016)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
62/174,005 11 June 2015 (11.06.2015) US
- (71) Applicants: **ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.** [US/US]; 1300 Morris Park Avenue, Bronx, NY 10461 (US). **ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI** [US/US]; One Gustave L. Levy Place, New York, NY 10029 (US). **MONTEFIORE MEDICAL CENTER** [US/US]; 111 East 210 Street, Bronx, NY 10467 (US).
- (72) Inventors: **SUN, Hui, B.**; 81 Bischoff Avenue, Chappaqua, NY 10514 (US). **FLATOW, Evan, L.**; 390 Riverside Drive, New York, NY 10025 (US). **WANICH, Tony**; 70 Anderson Avenue, Englewood Cliffs, NJ 07632 (US). **GRUSON, Konrad**; 330 East 70th Street, Apt. 5D, New York, NY 10021 (US). **ANDARAWIS-PURI, Nelly**; 1641 3rd Avenue, Apt. 9J, New York, NY 10128 (US).
- (74) Agents: **ARNOLD, Craig, J.** et al.; AMSTER, ROTHSTEIN & EBENSTEIN LLP, 90 Park Avenue, New York, NY 10016 (US).

- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: INTERVENTION FOR TENDINOPATHY

(57) Abstract: Methods for treating tendinopathy and tendonitis and for preventing tendinopathy are disclosed.



WO 2016/201162 A1

INTERVENTION FOR TENDINOPATHY

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims benefit of U.S. Provisional Application No. 62/174,005, filed June 11, 2015, the contents of which are hereby incorporated by reference.

STATEMENT OF GOVERNMENT SUPPORT

[0002] This invention was made with government support under grant numbers AG039561 awarded by the National Institutes of Health. The government has certain rights in the invention.

BACKGROUND OF THE INVENTION

[0003] Throughout this application various publications are referred to in brackets. Full citations for these references may be found at the end of the specification. The disclosures of these publications, and of all patents, patent application publications and books referred to herein, are hereby incorporated by reference in their entirety into the subject application to more fully describe the art to which the subject invention pertains.

[0004] The most common treatment for tendon ruptures is surgery. For tendinopathies, clinical treatments are less well-established. Possible treatments include icing, massage therapy, eccentric exercise, NSAIDs, ultrasound therapy, LIPUS, electrotherapy, taping, sclerosing injections, blood injection, glyceryl trinitrate patches, and extracorporeal shockwave therapy (ESWT). If not treated, tendinopathies can result in tendon rupture.

[0005] Herein is disclosed a method for using cells expressing CITED2 to treat tendinopathies and tendonitis.

SUMMARY OF THE INVENTION

[0006] A method is provided of treating a soft tissue degradation pathology in a subject comprising administering to the subject an amount of mesenchymal stem cells (MSCs) or tendon stem/progenitor cells (TSPCs) transfected to express CREB-binding protein/p300-interacting protein 2 (CITED2) to the subject effective to treat a soft tissue degradation pathology in a subject.

[0007] Also provided is a method of treating a tendinopathy in a subject comprising administering to the subject an amount of mesenchymal stem cells (MSCs) or tendon stem/progenitor cells (TSPCs) transfected to express CREB-binding protein/p300-interacting protein 2 (CITED2) to the subject effective to treat a tendinopathy in a subject.

[0008] Also provided is a method of determining the likelihood a tendon will suffer an injury or rupture due to aging comprising obtaining a sample of a tendon and quantifying the level of CREB-binding protein/p300-interacting protein 2 (CITED2) in the sample, and comparing the level to a predetermined control level for the sample size, and determining the likelihood the tendon will suffer an injury or rupture due to aging, wherein a level of CITED 2 quantitated in excess of the predetermined control level indicates that the tendon is not likely to suffer an injury or rupture due to aging and a level of CITED2 quantitated below the predetermined control level indicates that the tendon is likely to suffer an injury or rupture due to aging.

[0009] A method of determining the level of CREB-binding protein/p300-interacting protein 2 (CITED2) in a tendon comprising obtaining a sample of a tendon and quantifying the level of CREB-binding protein/p300-interacting protein 2 (CITED2) in the sample, and comparing the level to a predetermined control level for the sample size, and determining whether the level of CITED 2 quantitated is in excess of the predetermined control level or whether the level of CITED 2 quantitated is below the predetermined control level.

[0010] A method is provided for (i) improving integration between repaired and native tissue in a tendon, (ii) improving matrix organization in a tendon, (iii) promoting teno-differentiation phenotype in a tendon, (iv) reducing age-related senescence markers of aged implanted cells and cells from adjoining host tissue in a tendon, (v) elevating TGF- β and CTGF in a repaired tendon tissue, or (vi) treating a rupture in a tendon, wherein the tendon is in a subject, comprising administering to the subject an amount of mesenchymal stem cells (MSCs) or tendon stem/progenitor cells (TSPCs) transfected to express CREB-binding protein/p300-interacting protein 2 (CITED2) to the subject effective to (i) improve integration between repaired and native tissue in a tendon, (ii) improve matrix organization in a tendon, (iii) promote teno-differentiation phenotype in a tendon, (iv) reduce age-related senescence markers of aged implanted cells and cells from adjoining

host tissue in a tendon, (v) elevate TGF- β and CTGF in a repaired tendon tissue, or (vi) treat a rupture, respectively, in a tendon in a subject.

BRIEF DESCRIPTION OF THE DRAWINGS

[0011] Figure 1: Experimental design to evaluate therapeutic potential of CITED2 reprogramming of aged TSPCs.

[0012] Figure 2: Localization of human TSPCs in implanted wound site detected by imaging of fluorescently labelled TPSCs at 2 weeks following implantation, or by fluorescent detection of human chromosomes at 6 weeks after implantation.

[0013] Figure 3: Collagen fibril organization. Young TSPCs and TSPCs+CITED2 exhibited a more aligned collagen structure compared to tendons with no TSPCs and TSPCs transfected with a vector only.

[0014] Figure 4: Cell aspect ratio (width/length of cell, top) and cell angle orientation (difference in alignment between cell and tissue, bottom). Aged TSPCs+CITED2 and Young TSPCs showed a more elongated cell structure and better cellular alignment compared to the other groups. * $p < 0.05$ vs No TSPCs group. One-way ANOVA with Tukey's post hoc test. $n = 3/\text{group}$.

[0015] Figure 5: H&E staining of interface between repaired tissue and host tissue. A more seamless integration was observed between the repaired tissue and native tissue in tendons implanted with Aged TSPCs+CITED2 and Young TSPCs. $n = 3/\text{group}$.

[0016] Figure 6: Immunohistochemistry of tenocyte markers Scleraxis (Scx) and Tenomodulin (Tnmd). Injury implanted with Aged TSPCs+CITED2 or young TPSCs exhibited higher levels of Scx and Tnmd compared to the other groups. * $p < 0.05$ vs No TSPC group. One-way ANOVA with Tukey's post-hoc test. $n = 3/\text{group}$.

[0017] Figure 7: Immunohistochemistry of senescence marker Fucosidase A1 (FucA1) in repaired tissue. Injury implanted with Aged TSPCs+CITED2 or Young TSPCs exhibited lower levels of FucA1 in the repaired tissue. * $p < 0.05$ vs no TPSC group. One-way ANOVA with Tukey's post-hoc test. $n = 3/\text{group}$.

[0018] Figure 8: Immunohistochemistry of senescence marker Fucosidase A1 in host tissue. Injury implanted with Aged TSPCs+CITED2 or Young TSPCs exhibited lower levels of FucA1 in the host rat tissue. * $p < 0.05$ vs no TPSC group. One-way ANOVA with Tukey's post-hoc test. $n = 3/\text{group}$.

[0019] Figure 9A-9C: (9A) Maximum load (newtons, N) and (9B) maximum stress (megapascals, MPa) of full thickness lacerated rat Achilles tendons implanted with young or aged human TSPCs with or without CITED2 reprogramming, or implanted with no TPSCs. * $p < 0.05$ vs No TSPCs group. One-way ANOVA with Holm-Sidak's post-hoc test. $n = 5/\text{group}$. (9C) Max load of full thickness lacerated rat Achilles tendons implanted with young or aged human TSPCs with or without CITED2 reprogramming, or implanted with no TPSCs. * $p < 0.05$, vs indicated comparison. One-way ANOVA with Holm-Sidak's post-hoc test.

[0020] Figure 10: mRNA expression of human and rat TGF- β and CTGF in the rat host tissue and in the repaired tissue derived from implanted human TPSCs. * $p < 0.05$ vs indicated comparison. One-way ANOVA with Tukey's post-hoc test. $n = 3/\text{group}$.

[0021] Figure 11A-11E: Association between CITED2 expression (11A), Clonogenicity (11B), Nuclear aspect ratio (11C), Core area (11D), and percentage of senescent cells (11E) in TSPCs with increasing age in human.

[0022] Figure 12: CITED2 knockdown reduces colony forming ability of TSPCs.

[0023] Figure 13: CITED2 knockdown reduced proliferation rate and increased cell cycle arrest of TSPCs.

[0024] Figure 14: CITED2 knockdown altered cell cycle related gene expression in TSPCs.

[0025] Figure 15: CITED2 knockdown impaired tendon healing, following a window transection wound in patellar tendons in mice.

[0026] Figure 16A-C: (A) H&E, IHC for cleaved collagen (Col1C1, C2 [see arrowheads]), and Safranin O staining (red color) for GAGs. Scale bar=100 μm . (B) IHC for Col1a1 and Col3a1 (staining of extracellular matrix). (C) Gene expression analysis of Cited2, pro-inflammatory cytokines/mediators, neurovascularization-related factors, and genes involved in matrix synthesis and degradation. * $p < 0.05$ vs Sham (dotted line) or indicated comparison.

[0027] Figure 17A-B: (A) von Frey pain assessment and (B) gene expression of pro-inflammatory and pain mediators in DRG. * $p < 0.05$ vs sham (dotted line in [B]) or indicated comparison.

[0028] Figure 18A-B: (A) Max load and (B) maximum stress. * $p < 0.05$ vs sham or indicated comparison.

DETAILED DESCRIPTION OF THE INVENTION

[0029] Tendinopathy is a tendon disease associated with tendon aging and featured for inflammation and chronic injury. As evidenced herein (e.g. Figures 3-11), it is shown that increasing CITED2 levels (e.g. via gene transfer, cell-based therapy, chemical or physical induction) have a use as a tendinopathy treatment.

[0030] A method is provided of treating a soft tissue degradation pathology in a subject comprising administering to the subject an amount of mesenchymal stem cells (MSCs) or tendon stem/progenitor cells (TSPCs) transfected to express CREB-binding protein/p300-interacting protein 2 (CITED2) to the subject effective to treat a soft tissue degradation pathology in a subject. In an embodiment, the soft tissue is cartilage. In an embodiment, the soft tissue is a ligament. In an embodiment, the soft tissue is a tendon.

[0031] Also provided is a method of treating a tendinopathy in a subject comprising administering to the subject an amount of mesenchymal stem cells (MSCs) or tendon stem/progenitor cells (TSPCs) transfected to express CREB-binding protein/p300-interacting protein 2 (CITED2) to the subject effective to treat a tendinopathy in a subject.

[0032] In an embodiment of the methods described herein, the MSCs or TSPCs have been obtained from a human prior to their transfection to express CITED2. In an embodiment, the TSPCs are administered. In an embodiment, the MSCs are administered.

[0033] In an embodiment of the methods described herein, the MSCs or TSPCs have been obtained from a human biceps brachii tendon. Any other tendon in the human body is also an acceptable source of the cells.

[0034] The tendinopathy may be of an Achilles tendon, of a knee tendon or of an arm tendon.

[0035] In an embodiment of the methods described herein, the tendinopathy does not comprise a ruptured tendon. In an embodiment, the subject does not have a ruptured tendon.

[0036] In an embodiment of the methods described herein, the amount of the MSCs or TSPCs is administered directly to the tendon. In an embodiment of the methods described herein, the amount of the MSCs or TSPCs is implanted into, or directly adjacent to, the tendon.

[0037] In an embodiment of the methods described herein, the MSCs or TSPCs are obtained from an adult human prior to their transfection to express CITED2.

[0038] In an embodiment of the methods described herein, the tendinopathy comprises a tendinosis. In an embodiment of the methods described herein, the tendinopathy comprises a tendonitis.

[0039] In an embodiment of the methods described herein, the subject is a human.

[0040] Also provided is a method of determining the likelihood a tendon will suffer an injury or rupture due to aging comprising obtaining a sample of a tendon and quantifying the level of CREB-binding protein/p300-interacting protein 2 (CITED2) in the sample, and comparing the level to a predetermined control level for the sample size, and determining the likelihood the tendon will suffer an injury or rupture due to aging, wherein a level of CITED 2 quantitated in excess of the predetermined control level indicates that the tendon is not likely to suffer an injury or rupture due to aging and a level of CITED 2 quantitated in below the predetermined control level indicates that the tendon is likely to suffer an injury or rupture due to aging.

[0041] A method of determining the level of CREB-binding protein/p300-interacting protein 2 (CITED2) in a tendon comprising obtaining a sample of a tendon and quantifying the level of CREB-binding protein/p300-interacting protein 2 (CITED2) in the sample, and comparing the level to a predetermined control level for the sample size, and determining whether the level of CITED 2 quantitated is in excess of the predetermined control level or whether the level of CITED 2 quantitated is below the predetermined control level.

[0042] In the methods, the level of CITED2 in the sample can be quantified by determining by quantifying the amount of a polypeptide agent comprising an anti-CITED2 binding site that binds to the sample when contacted therewith. In an embodiment, the polypeptide agent comprising an anti-CITED2 binding site is an antibody or comprises an antigen-binding site of an antibody. In an embodiment, the agent comprising an anti-CITED2 binding site is labelled with a detectable marker molecule. Such markers are well known in the art, and include moieties such as radionuclides, fluorescent dyes, chemiluminescent agents, microparticles, nanoparticles, enzymes, colorimetric labels, magnetic labels, haptens, molecular beacons and aptamer beacons. Such detectable agents can also comprise antibodies or antibody fragments.

[0043] A method is provided for (i) improving integration between repaired and native tissue in a tendon, (ii) improving matrix organization in a tendon, (iii) promoting teno-

differentiation phenotype in a tendon, (iv) reducing age-related senescence markers of aged implanted cells and cells from adjoining host tissue in a tendon, (v) elevating TGF- β and CTGF in a repaired tendon tissue, or (vi) treating a rupture in a tendon, wherein the tendon is in a subject, comprising administering to the subject an amount of mesenchymal stem cells (MSCs) or tendon stem/progenitor cells (TSPCs) transfected to express CREB-binding protein/p300-interacting protein 2 (CITED2) to the subject effective to (i) improve integration between repaired and native tissue in a tendon, (ii) improve matrix organization in a tendon, (iii) promote teno-differentiation phenotype in a tendon, (iv) reduce age-related senescence markers of aged implanted cells and cells from adjoining host tissue in a tendon, (v) elevate TGF- β and CTGF in a repaired tendon tissue, or (vi) treat a rupture, respectively, in a tendon in a subject. Each of (i) to (v) are separable, individual embodiments of the method.

[0044] In an embodiment, the CITED2 is human CITED2. In an embodiment, and as used in the examples herein, the CITED2 contains is encoded by a cDNA of 1797 nucleotides (NM_001168388.2). In an embodiment, the CITED2 comprises the following sequence:

```
1 MADHMMAMNH GRFPDGTNGL HHHPAHRMGM GQFSPHHHQ QQQPQHAFNA LMGEHIHYGA
61 GNMNATSGIR HAMGPGTVNG GHPPSALAPA ARFNNSQFMG PPVASQGGSL PASMQLQKLN
121 NQYFNHHPYP HNHYPDLHP AAGHQMNGTN QHFRDCNPKH SGGSTPGGS GGSSTPGGSG
181 SSSGGGAGSS NSGGGSGSGN MPASVAHVPA AMLPPNVIDT DFIDEEVLMS LVIEMGLDRI
241 KELPELWLGG NEFDGMTDFV CKQQPSRVSC (SEQ ID NO:1) (NP_001161860.1).
```

[0045] In an embodiment, the CITED2 comprises the following sequence:

```
1 MSGLEMADHM MAMNHGRFPD GTNGLHHHPA HRMGMGQFPS PHHHQQQQPQ HAFNALMGEH
61 IHYGAGNMNA TSGIRHAMGP GTVNGGHPPS ALAPAAARFNN SQFMGPPVAS QGGSLPASMQ
121 LQKLNNQYFN HHPYPHNHYM PDLHPAAGHQ MNGTNQHFRD CNPKHSGGSS TPGGSGGSST
181 PGGSGSSSGG GAGSSNSGGG SGSGNMPASV AHVPAAMLPP NVIDTDFIDE EVLMSLVIEM
241 GLDRIKELPE LWLGQNEFDF MTDFVCKQQP SRVSC (SEQ ID NO:2) (NP_001161860.2)
```

[0046] Two methods (adenovirus transduction and plasmid transfection) were used for increasing CITED2 expression in TSPCs. Initial work herein mainly used the adenovirus for infection, which yielded high levels of CITED2 (8-10-fold increase). The results were confirmed with plasmid transfection, which gave a slightly lower overexpression level (2-4-fold increase with similar result), and better fit the purpose of restoring the CITED2 levels in adult tissues to young/physiological levels. For the plasmid transfection, TSPCs were transfected with CITED2 cDNA with a GFP tag (CMV-CITED2-GFP) using Lipofectamine

2000 following manufacturer's instructions. For the adenovirus infection, the recombinant adenovirus containing the CITED2 coding region was produced by the AdEasy system according to the manufacturer's instructions.

[0047] Tendon rupture is a tear of the tendon that requires surgical intervention in an attempt to restore tissue function. This is a significant clinical issue since tendon is a tissue difficult to heal. In most cases, after a long healing period, only results in formation of scar tissue, with reduced function and pain, and revision surgeries are often required. The intervention disclosed herein can provide the stem cell source which is needed for such an acute injury condition. Furthermore, CITED2-reprogrammed implanted stem cells will have enhanced repair ability to shorten the healing time and lead to genuine tendon repair, rather than generation of scar tissue. The technique disclosed herein can treat tendon rupture.

[0048] On the other hand, tendinopathy does not exhibit overt tissue damage induced by an acute event as seen in tendon rupture. Tendinopathy is defined as chronic tendon degeneration, in most cases due to tendon overload, leading to microscopic collagen fiber failure and a failed healing response. Accumulating evidence suggests the pathology behind tendinopathy is the dysfunction of tendon stem cells. The method disclosed herein can modulate dysfunction of tendinopathy-related cell disorders through CITED2 reprogramming. Such modulation includes correcting impaired stem cell function due to aging and altered response to stresses such as overloading and inflammation. The intervention will increase the reparative source with healthy reprogrammed stem cells. Furthermore, the implanted cells are able to improve the tendinopathy condition by reducing inflammatory and stressed microenvironment, enhancing extracellular matrix synthesis. Furthermore, evidence also shows the reprogrammed stem cells can restore function of the dysfunctional resident (host) stem cells and other cells through a paracrine mechanism. Thus, the methods disclosed herein provide a new tendinopathy treatment.

[0049] As used herein, "treating" a tendinopathy means that one or more symptoms of the disease, such as the tendinopathy itself, tendon strength, inflammation thereof, or other parameters by which the disease is characterized, are reduced, ameliorated, inhibited, placed in a state of remission, or maintained in a state of remission. Tendinopathies may be broadly categorized into those which are a tendonitis and those which are tendonosis.

[0050] This invention will be better understood from the examples follow. However, one skilled in the art will readily appreciate that the specific methods and results discussed

are merely illustrative of the invention as described more fully in the claims that follow thereafter.

Example 1

[0051] CITED2-reprogramming of aged stem cells for enhanced tendon rupture repair: It was investigated whether reprogramming of aged TSPCs would rejuvenate them and enhance their reparative ability. Wound healing was evaluated and the age-related and functional status of reparative and adjacent host tissue characterized of a full thickness rat Achilles wound created by laceration implanted with aged human TSPCs with or without CITED2 transfection in nude rats (Fig. 1).

[0052] CITED2 reprogrammed aged human TSPCs localized to the wound site and integrated with the repaired tendon after implantation (Fig. 2). The tendons implanted with CITED2 reprogrammed aged human TSPCs: exhibited improved collagen fibril organization (Fig. 3), improved cell/matrix organization (Fig. 4), improved integration between the native and repaired tissue (Fig. 5), upregulated expression of tenocyte markers (Fig. 6), and reduced expression of senescent markers in the repaired tissue (Fig. 7). Notably, senescence levels were also reduced in the host tissue in tendons implanted with CITED2 reprogrammed human TSPCs and young TSPCs (Fig. 8). Furthermore, tendons implanted with TSPCs overexpressing CITED2 exhibited stronger mechanical properties (Fig. 9). Specifically, all the treated groups showed a higher maximum load (Fig. 9A) and maximum stress (Fig. 9B) compared to the no TSPCs implanted group. Furthermore, CITED2 reprogrammed TSPCs had a higher maximum load compared to the non-CITED2 reprogrammed TSPCs for both old and young cells (Fig. 9C), suggesting that CITED2 reprogramming enhances tendon healing by improving tendon mechanical properties. CITED2 rejuvenates aged TSPC and aged tendon tissue through not only direct (i.e. physical microenvironment support) but also indirect (autocrine/paracrine) mechanisms as evidenced by elevation of TGF- β and CTGF in both human- and rat-derived components in the repaired tissue (Fig. 10).

[0053] These data show CITED2 reprogramming enhances TSPC reparative ability and promotes rejuvenation of aged human TSPCs and adjacent rat tissue. Based on the mechanical property testing, such as maximum load, CITED2 reprogramming increased the reparability of both old and young TSPCs, leading to a better wound healing outcome with

stronger mechanical properties. Effects of CITED2 reprogramming are mediated, at least in part, through paracrine mechanisms.

[0054] In conclusion, CITED2-reprogrammed TSPCs are a solution for tendon injury repair and tendon aging. CITED2 reprogrammed human TSPCs:

- Improved integration between repaired and native tissue
- Improved matrix organization
- Promoted teno-differentiation phenotype
- Reduced age-related senescence marker of aged implanted cells and cells from adjoining host tissue
- Elevated TGF- β and CTGF in both human and rat-derived repaired tissue.

Example 2

[0055] CITED2 as a tendon aging marker for status and susceptibility for tendinopathy and rupture: It was determined whether the level of CITED2 expression in TSPCs can be used as a tendon-aging marker. The relationship between level of CITED2 expression in TSPC and tendon aging in human tendons was established and then it was determined whether reduction of Cited2 leads to an aging phenotype in Cited2 haploinsufficient (Cited2^{+/-}) mice.

[0056] Levels of CITED2 expression in TSPCs at both the mRNA and protein levels is reversely associated with tendon aging in human (Fig. 11A). Furthermore, the number of cells/colony (Fig. 11B), nuclear aspect ratio (Fig. 11C), cell area (Fig. 11D), and percentage of senescent cells (Fig. 11E) of TSPC *in vitro* culture are also reversely associated with tendon aging.

[0057] Cited2 haploinsufficient (Cited2^{+/-}) mice exhibit aging phenotype, characterized by: a reduction in colony forming ability (Fig. 12), reduced proliferation rate and increased cell cycle arrest (Fig. 13), altered cell cycle related gene expression (Fig. 14), and impaired tendon healing (Fig. 15).

[0058] These data indicate CITED2 expression in TSPCs is reversely associated with tendon aging. Reductions of CITED2 leads to an aging phenotype including impaired wound healing, supporting that declining levels of CITED2 expression is a function of aging. Because aging is a risk factor for the onset of tendon wound injuries, CITED2 as a tendon aging marker may also be used as an indicator for the susceptibility for injury such as rupture and tendinopathy. In conclusion, CITED2 expression is associated with tendon

aging that may be used as an indicator for tendon injury status and tendon injury susceptibility.

Methods

[0059] Tendon stem/progenitor cells (TSPCs) are identified and isolated as previously described (Zhou et al. *Aging Cell*, Oct;9(5):911-5, 2010). Briefly, the fresh tendon tissue sample is cut into small pieces (1 mm × 1 mm × 1 mm or smaller). The tissues were digested with collagenase/dispase (Roche) in phosphate-buffered saline (PBS) at 37°C for 2 hrs. The suspensions were centrifuged at 1,500 g for 15 min, and the supernatant was discarded. The remaining cell pellet was re-suspended in growth medium consisting of Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS). A single-cell suspension was obtained by diluting the suspension and then cultured in 6-well plates at 37°C with 5% CO₂. The culture medium is replaced with fresh medium every 2 days. After 8-10 days in culture, cell colonies are formed on the culture surface of the plate. The cells that exhibit a cobblestone shape are the TSPCs, and are designated as passage 0 (P0). The TSPCs may exhibit morphological characteristics and express stem cell markers such as octamer-binding transcription factor 4 (Oct-4), Stage-specific embryonic antigen-4 (SSEA-4), and nucleostemin, as assayed by reverse transcription real-time PCR at the mRNA level and immunocytochemistry staining or Western blot at the protein level. TSPCs showed the typical mesenchymal phenotype, with high expression of CD73, CD90 and CD105 and no expression of CD34 and CD45 by flow cytometry. TSPCs may exhibit morphological characteristics and express stem cell markers in culture for at least 10 passages (p10). P2 and P3 were used for the treatment in this application.

[0060] Mesenchymal stem cells (MSCs), such as bone marrow derived MSCs are identified and isolated following the standard methods (Soleimani and Nadri. *Nature Protocols* 2009;4(1):102-6.). Briefly, bone marrow is flushed out the bone with cut ends with DMEM + 10% FBS. The cell suspension is filtered through a 70 mm mesh. MSCs are cultured in 100mm dishes in 1ml at a density of 25×10^6 cells/ml, and incubated at 37°C with 5% CO₂ in a humidified chamber. After 3 hours, nonadherent cells are removed and the medium is replaced with fresh DMEM + 10% FBS. Culture medium is replaced every 8 hours, for up to 72 hours of culture, and then replaced every 3 days thereafter. Adherent cells are designated as MSCs, at passage 0, and will exhibit a spindle-shaped morphology. Based on flow cytometry, MSCs will express Stro-1, CD271, SSEA-4, CD146, CD105,

CD73, and CD90, and negative for CD45, CD34, CD14, CD11b, CD79a [Kohler et al. Aging Cell, 12(6):988-999].

Example 3

[0061] CITED2 reprogrammed stem cells slow disease progression and relieve pain in tendinopathy: Using a well-established Achilles tendinopathy model [5], the action of CITED2-modulated TSPCs was examined on improved pathogenesis and symptoms of tendinopathy, and tendon mechanical properties and function.

[0062] Methods: Human TSPCs (hTSPCs) were isolated from biceps brachii tendons of patients (62-68yrs) undergoing total shoulder replacement (n=6) and used at passage 3 or below. TSPCs (5×10^5) were transfected with either plasmid containing CITED2 cDNA or a vector control and injected into the site of tendinopathy in the Achilles, 3 days after collagenase-induced tendinopathy (Sprague Dawley rats, 5-6 months, male), according to IACUC protocol. Four weeks after tendinopathy induction, von Frey testing examined mechanical allodynia to assess pain [6]. At sacrifice, samples were harvested for histology (H&E) and immunohistochemistry (n=3/group), mechanical testing (n=6/group), and RT-qPCR analysis (n=6/group) for genes of pro-inflammatory cytokines and mediators related to matrix degradation and neurovascularization in tendinopathy. An ANOVA with Tukey post-hoc test was utilized to determine statistical significance.

[0063] Results: Tendon tissue injected with TSPCs exhibited disease and symptom improvement compared with the vehicle control, while treatment with TSPCs overexpressed with CITED2 exhibited improved histology, immunohistochemistry and mechanical properties, similar to sham controls, with reduced pain/functional behavior. Specifically, the disease site of the TSPC+CITED2 group had: 1) improved morphology with reduced cellularity, better alignment of cell and matrix fibers, reduced collagen cleavage (Col1C1, C2), reduced GAG content (Fig. 16A), increased Col1a1 and reduced Col3a1 staining (Fig. 16B), and a significant reduction in gene expression for genes such as Tnfa, Mmp9 and 13 (pro-inflammatory cytokines/mediators), Hif1a, Vegf (vascularization) and Ngf, Bdnf, mglur2, and mglur7 (nerve ingrowth); 2) pain relief, as indicated by reduced sensitivity to mechanical insult (mechanical allodynia), and reduced expression of neuropathic-related transmitters in the dorsal root ganglion (DRG), which contains bodies of sensory neurons innervating the Achilles tendon; (Fig. 17; 18) improved Achilles tendon

mechanical properties as indicated by a higher maximum load (Fig. 18A) and maximum stress (Fig. 18B).

[0064] Thus it was demonstrated that CITED2-modulated stem cell treatment significantly improves not only tendinopathy pathology, but also the mechanical properties of the tendon, and relieved pain symptoms in a rat Achilles tendinopathy model. CITED2 modulates a panel of genes that are highly relevant to tendinopathy progression and symptom development, supporting its therapeutic effect for tendinopathy.

[0065] References

1. Magnusson et al. Nature Rev Rheum, 2010.
2. Cook and Purdam. Br J Sports Med. 2013.
3. Zhou et al. Aging Cell, 2010.
4. Saad et al. ORS 2013.
5. Chen et al. Cell Physiol Biochem, 2014.
6. Leong et al. Arthritis Res Ther, 2014.

What is claimed is:

1. A method of treating a soft tissue degradation pathology in a subject comprising administering to the subject an amount of mesenchymal stem cells (MSCs) or tendon stem/progenitor cells (TSPCs) transfected to express CREB-binding protein/p300-interacting protein 2 (CITED2) effective to treat a soft tissue degradation pathology in a subject.
2. The method of Claim 1, wherein the soft tissue is cartilage, a ligament or a tendon.
3. A method of treating a tendinopathy in a subject comprising administering to the subject an amount of mesenchymal stem cells (MSCs) or tendon stem/progenitor cells (TSPCs) transfected to express CREB-binding protein/p300-interacting protein 2 (CITED2) effective to treat a tendinopathy in a subject.
4. The method of any of Claims 1-3, wherein the MSCs or TSPCs have been obtained from a human prior to their transfection to express CITED2.
5. The method of any of Claims 1-4, wherein the MSCs or TSPCs have been obtained from a human biceps brachii tendon.
6. The method of any of Claims 3-5, wherein the tendinopathy is of an Achilles tendon, a knee tendon or an arm tendon.
7. The method of any of Claims 3-6, wherein the tendinopathy does not comprise a ruptured tendon.
8. The method of any of Claims 3-7, wherein the amount of the MSCs or TSPCs is administered directly to the tendon.
9. The method of any of Claims 3-8, wherein the amount of the MSCs or TSPCs is implanted into, or directly adjacent to, the tendon.

10. The method of any of Claims 3-9, wherein the MSCs or TSPCs are obtained from an adult human prior to their transfection to express CITED2.
11. The method of any of Claims 3-10, wherein the tendinopathy comprises a tendinosis.
12. The method of any of Claims 3-10, wherein the tendinopathy comprises a tendonitis.
13. The method of any of Claims 1-12, wherein the subject is a human.
14. The method of any of Claims 1-13, wherein the MSCs are administered.
15. The method of any of Claims 1-13, wherein the TSPCs are administered.
16. A method of determining the likelihood a tendon will suffer an injury or rupture due to aging comprising obtaining a sample of a tendon and quantifying the level of CREB-binding protein/p300-interacting protein 2 (CITED2) in the sample, and comparing the level to a predetermined control level for the sample size, and determining the likelihood the tendon will suffer an injury or rupture due to aging, wherein a level of CITED 2 quantitated in excess of the predetermined control level indicates that the tendon is not likely to suffer an injury or rupture due to aging and a level of CITED 2 quantitated below the predetermined control level indicates that the tendon is likely to suffer an injury or rupture due to aging.
17. A method of determining the level of CREB-binding protein/p300-interacting protein 2 (CITED2) in a tendon comprising obtaining a sample of a tendon and quantifying the level of CREB-binding protein/p300-interacting protein 2 (CITED2) in the sample, and comparing the level to a predetermined control level for the sample size, and determining whether the level of CITED 2 quantitated is in excess of the predetermined control level or whether the level of CITED 2 quantitated is below the predetermined control level.

18. The method of Claim 16 or 17, wherein the level of CITED2 in the sample is quantified by determining by quantifying the amount of a polypeptide agent comprising an anti-CITED2 binding site that binds to the sample when contacted therewith.

19. The method of Claim 18, wherein the polypeptide agent comprising an anti-CITED2 binding site is an antibody or comprises an antigen-binding site of an antibody.

20. The method of Claim 18 wherein the agent comprising an anti-CITED2 binding site is labelled with a detectable marker molecule.

21. A method for (i) improving integration between repaired and native tissue in a tendon, (ii) improving matrix organization in a tendon, (iii) promoting teno-differentiation phenotype in a tendon, (iv) reducing age-related senescence markers of aged implanted cells and cells from adjoining host tissue in a tendon, (v) elevating TGF- β and CTGF in a repaired tendon tissue, or (vi) treating a rupture in a tendon,


wherein the tendon is in a subject, comprising administering to the subject an amount of mesenchymal stem cells (MSCs) or tendon stem/progenitor cells (TSPCs) transfected to express CREB-binding protein/p300-interacting protein 2 (CITED2) to the subject effective to (i) improve integration between repaired and native tissue in a tendon, (ii) improve matrix organization in a tendon, (iii) promote teno-differentiation phenotype in a tendon, (iv) reduce age-related senescence markers of aged implanted cells and cells from adjoining host tissue in a tendon, (v) elevate TGF- β and CTGF in a repaired tendon tissue, or (vi) treat a rupture, respectively, in a tendon in a subject.

1/23


Experimental design

Nude rat tendon injury model

- Male, 10-12 months old, nude rats n=3/group
- Complete transverse Achilles transection

Okamoto et al. JBJS, 2010

Experimental protocol



TSPC reprogramming and implantation

10^6 Human TSPCs labeled with PKH26 fluorescent dye and implanted in fibrin hydrogel

Experimental groups

- Aged human TSPCs transduced with CITED2
- Aged human TSPCs transduced with control vector
- Young human TSPCs
- No TSPCs

FIG. 1

2/23





FIG. 2

3/23

Improved collagen fibril organization


Polarized light images of tendon tissues stained Picro Sirius Red

Scale bar = 50 μ M

FIG. 3

Improved cell/matrix organization

Cell aspect ratio (width/length)



Cell angle orientation
(Difference in alignment between cell and tissue)




FIG. 4

5/23

Improved integration between native and repaired tissue








FIG. 5

Upregulates expression of tenocyte markers

Scleraxis — early tenocyte differentiation marker



Tenomodulin — late/mature tenocyte differentiation marker



Scale bar = 50µM


(*: p<0.05)

FIG. 6


7/23

Reduces expression of senescent marker in repaired tissue

Fucosidase A1 (FucA1; cell senescence marker)



Scale bar = 50 μ M



(*: $p < 0.05$)

FIG. 7

8/23

Reduces expression of senescent marker in **host** tissue

Fucosidase A1 (FucA1)



(*: $p < 0.05$)

FIG. 8

9/23




FIG. 9A

10/23




FIG. 9B

11/23





FIG. 9C

Increased levels of both human and rat TGF- β and CTGF



TGF- β and CTGF expression are elevated in both human and rat derived tissues, suggesting a paracrine mechanism crossing human TSPCs derived tissue and rat derived or native tissue.

(*: p<0.05)

FIG. 10




FIG. 11A




FIG. 11B

14/23




FIG. 11C




FIG. 11D





FIG. 11E

15/23

Reduction in colony forming ability

- Cited2^{+/-}: CITED2-haploinsufficient mice



- Loss-of-function: deficiency mimic aged TSPCs.

Wild Type, WT: CITED2^{+/+}, male mice at 20-weeks of age


FIG. 12

16/23

Reduced proliferation rate and increased cell cycle arrest

WT vs Cited2^{+/-}

Proliferation rate



Human TSPCs CITED2 knockdown

Proliferation rate





FIG. 13A

17/23

Reduced proliferation rate and increased cell cycle arrest

Cell cycle analysis



Cell cycle analysis




FIG. 13B

Altered cell cycle related gene expression




FIG. 14

Impaired tendon healing

- Four weeks after punch hole (0.75mm) injury




FIG. 15D

FIG. 15E

20/23




FIG. 16A




FIG. 16B




FIG. 16C




FIG. 17A




FIG. 17B




FIG. 18A




FIG. 18B

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 16/36786

A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - C12N 5/0775, C12N 15/86 (2016.01)

CPC - C12N 5/0652, C12N 5/0669, C12N 5/0663, A61K 39/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC (8): C12N 5/0775, C12N 15/86 (2016.01)

CPC: C12N 5/0652, C12N 5/0669, C12N 5/0663, A61K 39/00

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
USPC: 435/6.17, 506/16

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Google patents, Google scholar, Google web, PatBase, Proquest Dialog

Tendinopathy/tendonitis; soft tissue/cartilage/ligament/tendon; degradation/rupture/pathology; treat/ameliorate; administer; transfected; mesenchymal stem cells/MSC/tendon stem/progenitor cells/TSPCs; CREB-binding protein/p300-interacting protein 2/CITED2; level

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SAAD et al. "CITED2 rejuvenates aged tendon stem/progenitor Cells (TSPC) and repaired aged tendon tissue through a novel paracrine mechanism" 2014 ORS Annual Meeting Poster No: 0115 [Retrieved on 4 September 2016] Retrieved from website <URL: http://www.ors.org/Transactions/60/0115.pdf > especially, page 1, para 1-3; page 1, para 4; page 2, para 1-2	1-2, 4/(1-2), 21
Y		3, 4/3
X	ZHOU et al. "CITED2 is essential for tendon-derived stem cell self-renewal" ORS Annual Meeting Paper No. 49. 2011 [Retrieved on 4 September 2016] Retrieved from website <URL: http://www.ors.org/Transactions/57/0049.pdf > especially, page 1, Col. 1, para 2; page 1, Col. 1, para 4; Fig. 2; page 1, Col. 2, para 2	16-20
Y	SUN et al. "Biology and mechano-response of tendon cells: progress overview and perspectives" J Orthop Res. (1 June 2015) Vol. 33. No. 6. pp Pages 785-792, pg 788, col 1, para 5, pg 189, col 2, para - pg 190, col 1	3, 4/3

☐

Further documents are listed in the continuation of Box C.

☐

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

5 September 2016 (05.09.2016)

Date of mailing of the international search report

03 OCT 2016

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450

Facsimile No. 571-273-8300

Authorized officer:

Lee W. Young

PCT Helpdesk: 571-272-4300
PCT OSP: 571-272-7774

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 16/36786

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☒ Claims Nos.: 5-15
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.